Safety of abemaciclib in HR+ and HER2- breast cancer | CMAR
Why was this study done? Breast cancers that express hormone receptors (HR+) but not the human epidermal growth factor receptor 2 (HER2-) are generally initially sensitive to hormone therapies. These...
Conclusion: Abemaciclib was well tolerated in Japanese patients in MONARCH 2 and MONARCH 3, with common, clinically relevant TEAEs manageable with appropriate interventions.
Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35327452/
The regulatory and functional roles of non-coding RNAs are increasingly demonstrated as critical in cancer. Among non-coding RNAs, microRNAs (miRNAs) are the most well-studied with direct regulation of biological signals...
Conclusion/Relevance: In this review, we discuss the altered miRNA landscape in the context of breast cancer and propose that breast cancer subtypes have distinct miRNA dysregulation. Further, given that miRNAs can be used as diagnostic and/or prognostic biomarkers, their impact as novel targets for subtype-specific therapy is also possible and...
High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35329928/
1 Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, ON P6B 0A8, Canada. 2 Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury,...
Conclusions: These data may inform the potential suitability of these cancers for immunotherapy and could guide the development of rational combination therapies based on immune checkpoint inhibitors with other targeted drugs.
Targeting CDK4/6 for Anticancer Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35327487/
Cyclin-dependent kinase 4/6 (CDK4/6) are key regulators of the cell cycle and are deemed as critical therapeutic targets of multiple cancers. Various approaches have been applied to silence CDK4/6 at...
Conclusion/Relevance: We describe approaches to combat drug resistance, including combination therapy and PROTACs drugs that degrade the kinases. Finally, critical issues and perspectives in the field are outlined.
Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35330381/
Abemaciclib significantly improves invasive disease-free survival when combined with endocrine therapy in clinical high-risk patients with HR+/Her2- early breast cancer (eBC). The objective of the following study was to model...
Conclusion/Relevance: Breast care units are facing a significant patient burden, since the 2-year abemaciclib therapy requires regular monitoring of toxicities. Specific care concepts to strengthen therapy adherence as well as further studies to deescalate adjuvant systemic treatment and individualize CDK 4/6 inhibitor therapy are therefore...